Beamion LUNG-2: ゾンゲルチニブ (BI 1810631) が標準治療と比較して、HER2 変異を持つ進行性非小細胞肺がん患者を助けるかどうかを試験する研究
Beamion LUNG-2: 切除不能、局所進行性または転移性の非扁平上皮非扁平上皮疾患患者の第一選択治療として経口投与された BI 1810631 を標準治療と比較して評価する第 III 相、非盲検、無作為化、実薬対照、多施設共同試験HER2 チロシンキナーゼドメイン変異を有する小細胞肺がん
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy.
Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein.
Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
調査の概要
状態
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Huntsville、Alabama、アメリカ、35805
- Clearview Cancer Institute
-
-
Arizona
-
Bullhead City、Arizona、アメリカ、86442
- Pioneer Research Center - Bullhead City
-
-
California
-
Beverly Hills、California、アメリカ、90212
- Precision NextGen Oncology
-
Fresno、California、アメリカ、93710
- ClinRé 001-022 (Premier Cancer Care and Infusion Center)
-
Glendale、California、アメリカ、91203
- OPN Healthcare, Inc.
-
La Jolla、California、アメリカ、92037
- Scripps Green Hospital
-
Los Angeles、California、アメリカ、90067
- Valkyrie Clinical Trials
-
San Diego、California、アメリカ、92123
- Sharp Memorial Hospital
-
-
Missouri
-
Bridgeton、Missouri、アメリカ、63044
- St. Louis Cancer Care, LLP
-
Springfield、Missouri、アメリカ、65807
- Oncology Hematology Associates
-
-
Nevada
-
Reno、Nevada、アメリカ、89511
- Cancer Care Specialists
-
-
New York
-
Lake Success、New York、アメリカ、11042
- Northwell Health
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center
-
-
North Carolina
-
Wilson、North Carolina、アメリカ、27893
- Regional Medical Oncology Center
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- Gabrail Cancer Center
-
-
South Carolina
-
Rock Hill、South Carolina、アメリカ、29732
- Carolina Blood and Cancer Care Associates, PA
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- SCRI Oncology Partners
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Virginia Cancer Specialists, PC
-
-
Washington
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute
-
Seattle、Washington、アメリカ、98104
- Swedish Cancer Institute
-
-
-
-
-
CABA、アルゼンチン、1430
- Clinica Adventista Belgrano
-
Ciudad Autónoma de Bs As、アルゼンチン、C1426ANZ
- Instituto Medico Especializado Alexander Fleming
-
Córdoba、アルゼンチン、X5000
- Instituto Oncologico de Cordoba
-
La Rioja、アルゼンチン、F5300COE
- Centro Oncologico Riojano Integral (CORI)
-
Rosario、アルゼンチン、S2000DEJ
- Instituto Medico de la Fundacion Estudios Clinicos
-
-
-
-
-
Edinburgh、イギリス、EH4 2XU
- Western General Hospital
-
Leicester、イギリス、LE1 5WW
- Leicester Royal Infirmary
-
London、イギリス、SE1 9RT
- Guy's Hospital
-
London、イギリス、SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
Sutton、イギリス、SM2 5PT
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Haifa、イスラエル、3109601
- Rambam Medical Center
-
Kfar Saba、イスラエル、4428164
- Meir Medical Center
-
Petah Tikva、イスラエル、49100
- Rabin Medical Center Beilinson
-
Tel Aviv、イスラエル、6423906
- Sourasky Medical Center
-
-
-
-
-
Bari、イタリア、70124
- Istituto Tumori Giovanni Paolo II
-
Candiolo (TO)、イタリア、10060
- Istituto Di Candiolo
-
Catania、イタリア、95123
- Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
-
Naples、イタリア、80131
- Istituto Nazionale IRCCS Tumori Fondazione Pascale
-
Parma、イタリア、43100
- Azienda Ospedaliera Unversitaria di Parma
-
Roma、イタリア、00161
- AOU Policlinico Umberto I
-
Varese、イタリア、21100
- A. O. Ospedale Circolo Fond. Macchi
-
-
-
-
-
Amsterdam、オランダ、1066 CX
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL)
-
Maastricht、オランダ、6229 HX
- Maastricht University Medisch Centrum
-
-
-
-
New South Wales
-
Randwick、New South Wales、オーストラリア、2031
- Prince of Wales Hospital-Randwick-66496
-
St Leonards、New South Wales、オーストラリア、2065
- Royal North Shore Hospital-St Leonards-20807
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- Princess Alexandra Hospital
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- Austin Health
-
-
Western Australia
-
Subiaco、Western Australia、オーストラリア、6008
- St John of God Subiaco Hospital
-
-
-
-
-
Krems、オーストリア、3500
- Krems University Hospital
-
Vienna、オーストリア、1210
- Clinic Floridsdorf
-
-
-
-
-
Singapore、シンガポール、168583
- National Cancer Centre Singapore
-
Singapore、シンガポール、119228
- National University Hospital-Singapore-22806
-
-
-
-
-
Gothenburg、スウェーデン、413 45
- Sahlgrenska Universitetsjukhuset
-
Stockholm、スウェーデン、171 76
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
A Coruña、スペイン、15006
- Complejo Hospitalario Universitario A Coruña
-
Alicante、スペイン、03010
- Hospital General Universitario de Alicante
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
Barcelona、スペイン、08026
- Hospital Santa Creu i Sant Pau
-
Barcelona、スペイン、08908
- Hospital Duran i Reynals
-
Bilbao、スペイン、48013
- Hospital de Basurto
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28046
- Hospital Universitario La Paz
-
Madrid、スペイン、28009
- Hospital General Universitario Gregorio Marañón
-
Madrid、スペイン、28034
- Hospital Universitario Ramon Y Cajal
-
Málaga、スペイン、29010
- Hospital Regional Universitario de Malaga
-
Seville、スペイン、41013
- Hospital Virgen del Rocio
-
Valencia、スペイン、46010
- Hospital Clinico Universitario de Valencia
-
-
-
-
-
Recoleta、チリ、8420383
- Bradford Hill- Centro de Investigacion Clinica
-
-
-
-
-
Augsburg、ドイツ、86156
- Universitätsklinikum Augsburg
-
Berlin、ドイツ、14089
- Gemeinschaftskrankenhaus Havelhöhe gGmbH
-
Cologne、ドイツ、50937
- Universitätsklinikum Köln (AöR)
-
Dresden、ドイツ、01307
- Universitätsklinikum Carl Gustav Carus Dresden
-
Giessen、ドイツ、35392
- Justus-Liebig Universität Gießen
-
Heidelberg、ドイツ、69126
- Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
-
Oldenburg、ドイツ、26121
- Pius-Hospital, Oldenburg
-
Tübingen、ドイツ、72076
- Universitätsklinikum Tübingen
-
-
-
-
-
Drammen、ノルウェー、N-3004
- Vestre Viken HF, Drammen Sykehus
-
Oslo、ノルウェー、0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Bron、フランス、69677
- Hopital Louis Pradel
-
Lyon、フランス、69373
- CTR Leon Berard
-
Marseille、フランス、13015
- HOP Nord
-
Paris、フランス、75248
- INS Curie
-
Paris、フランス、75020
- HOP Tenon
-
Rennes、フランス、35000
- HOP Pontchaillou
-
Strasbourg、フランス、67091
- HOP Civil
-
Toulouse、フランス、31059
- Hôpital Larrey - CHU de Toulouse
-
Villejuif、フランス、94805
- Institut Gustave Roussy
-
-
-
-
-
Bento Gonçalves、ブラジル、95700-084
- Associacao Dr. Bartholomeu Tacchini
-
Londrina、ブラジル、86015-520
- Hospital do Câncer de Londrina
-
Porto Alegre、ブラジル、90610-000
- Hospital Sao Lucas da PUCRS
-
Rio de Janeiro、ブラジル、22250-905
- OncoClinicas Rio de Janeiro
-
Santo André、ブラジル、09060-650
- CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
-
São José do Rio Preto、ブラジル、15090-000
- Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
São Paulo、ブラジル、01246-000
- ICESP - Instituto do Cancer do Estado de Sao Paulo
-
-
-
-
-
Rio Piedras、プエルトリコ、00935
- Pan American Center for Oncology Trials, LLC
-
-
-
-
-
Anderlecht、ベルギー、1070
- Brussels - HOSP Jules Bordet
-
Ghent、ベルギー、9000
- Universitair Ziekenhuis Gent
-
Leuven、ベルギー、3000
- UZ Leuven
-
-
-
-
-
Lisbon、ポルトガル、1350-352
- Hospital CUF Tejo
-
Lisbon、ポルトガル、1769-001
- Centro Hospitalar Lisboa Norte Hospital Pulido Valente
-
Porto、ポルトガル、4100-180
- Hospital CUF Porto
-
-
-
-
-
Lodz、ポーランド、93-338
- Polish Mother's Memorial Hospital - Research Institute
-
Poznan、ポーランド、60-569
- Greater Poland Center of Pulmonology and Thoracic Surgery
-
Poznan、ポーランド、60693
- Med Polonia Sp. z o.o
-
Warsaw、ポーランド、02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Mexico City、メキシコ、03100
- Health Pharma Professional Research S.A. de C.V.
-
México、メキシコ、14080
- Instituto Nacional de Cancerologia
-
México、メキシコ、06760
- Centro Oncologico Personalizado
-
Veracruz、メキシコ、91900
- FAICIC S de RL de C.V.
-
-
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Beijing、中国、1000021
- Cancer Hospital of Chinese Academy of Medical Science
-
Chengdu、中国、610042
- West China Hospital, Sichuan University
-
Fuzhou、中国、350014
- Fujian Cancer Hospital
-
Guangzhou、中国、510080
- Guangdong Provincial People's Hospital
-
Hangzhou、中国、310022
- Zhejiang Cancer Hospital
-
Hangzhou、中国、310003
- The First Affiliated Hospital, Zhejiang University
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
Harbin、中国、150081
- Harbin Medical University Cancer Hospital
-
Shanghai、中国、200032
- Fudan University Shanghai Cancer Center
-
Shanghai、中国、200032
- Zhongshan Hospital Affiliated to Fudan University
-
Taizhou、中国、317099
- Taizhou Hospital of Zhejiang Province
-
Wenzhou、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan、中国、430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xiamen、中国、361003
- First Affiliated Hospital of Xiamen University
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung、台湾、404
- Chung Shan Medical University Hospital
-
Taipei、台湾、100
- National Taiwan University Hospital
-
Taipei、台湾、106
- National Taiwan University Cancer Center
-
Taoyuan、台湾、330
- Chang Gung Memorial Hospital, Linkou
-
-
-
-
-
Aichi, Nagoya、日本、464-8681
- Aichi Cancer Center Hospital
-
Aomori, Hirosaki、日本、036-8563
- Hirosaki University Hospital
-
Chiba, Kashiwa、日本、277-8577
- National Cancer Center Hospital East
-
Ehime, Matsuyama、日本、791-0280
- Shikoku Cancer Center
-
Fukuoka, Fukuoka、日本、812-8582
- Kyushu University Hospital
-
Hokkaido, Hakodate、日本、040-8611
- Hakodate Goryoukaku Hospital
-
Hokkaido, Sapporo、日本、003-0804
- Hokkaido Cancer Center
-
Ishikawa, Kanazawa、日本、920-8641
- Kanazawa University Hospital
-
Kanagawa, Kawasaki、日本、216-8511
- St. Marianna University Hospital
-
Kanagawa, Yokohama、日本、241-8515
- Kanagawa Cancer Center
-
Kyoto, Kyoto、日本、602-8566
- University Hospital Kyoto Prefectural University of Medicine
-
Miyagi, Sendai、日本、980-8574
- Tohoku University Hospital
-
Okayama, Okayama、日本、700-8558
- Okayama University Hospital
-
Osaka, Osaka、日本、541-8567
- Osaka International Cancer Institute
-
Shizuoka, Sunto-gun、日本、411-8777
- Shizuoka Cancer Center
-
Tokyo, Bunkyo-ku、日本、113-8431
- Juntendo University Hospital
-
Tokyo, Bunkyo-ku、日本、113-8677
- Komagome Hospital
-
Tokyo, Chuo-ku、日本、104-0045
- National Cancer Center Hospital
-
Tokyo, Koto-ku、日本、135-8550
- Japanese Foundation for Cancer Research
-
Wakayama, Wakayama、日本、641-8510
- Wakayama Medical University Hospital
-
-
-
-
-
Cheongiu、韓国、28644
- Chungbuk National University Hospital
-
Goyang、韓国、10408
- National Cancer Center
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、03181
- Kangbuk Samsung Hospital
-
Seoul、韓国、03722
- Severance Hospital
-
Suwon、韓国、16247
- The Catholic University of Korea, St.Vincent's Hospital
-
-
-
-
-
Hong Kong、香港、999077
- Queen Mary Hospital
-
Hong Kong、香港、999077
- Princess Margaret Hospital
-
Hong Kong、香港、51727
- Queen Elizabeth Hospital-Hong Kong-51727
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
- Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
- Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
- Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
- An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
- Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
- Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.
- Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information.
Further inclusion criteria apply.
Exclusion criteria:
-
Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ
- other effectively treated malignancy that is considered cured by local treatment
-
Tumors with targetable alterations with approved available therapy.
-
Lung-specific intercurrent clinically significant severe illness based on investigators assessment.
-
Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
-
Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.
-
Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.
-
History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.
-
Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.
Further exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental treatment arm
zongertinib only |
zongertinib
他の名前:
|
|
アクティブコンパレータ:Comparator arm
pembrolizumab plus platinum-pemetrexed chemotherapy |
pembrolizumab
他の名前:
platinum-pemetrexed chemotherapy platinum-pemetrexed chemotherapy platinum-pemetrexed chemotherapy |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review
時間枠:up to 4 years and 5 months
|
PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier. |
up to 4 years and 5 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
NSCLC-SAQ呼吸困難ドメインスコアのベースラインから25週目までの変化
時間枠:ベースライン、25週目
|
ベースライン、25週目
|
|
|
NSCLC-SAQ咳嗽領域スコアのベースラインから25週目までの変化
時間枠:ベースライン、25週目
|
ベースライン、25週目
|
|
|
NSCLC-SAQ 食欲ドメインスコアのベースラインから 25 週目までの変化
時間枠:ベースライン、25週目
|
ベースライン、25週目
|
|
|
NSCLC-SAQ疲労領域スコアのベースラインから25週目までの変化
時間枠:ベースライン、25週目
|
ベースライン、25週目
|
|
|
治療期間中の有害事象 (AE) の発生。有害事象共通用語基準 (CTCAE) バージョン 5.0 に従って等級分けされます。
時間枠:最長53ヶ月
|
最長53ヶ月
|
|
|
CTCAE バージョン 5.0 に従って等級付けされた、治療期間中の重篤な AE (SAE) の発生
時間枠:最長53ヶ月
|
最長53ヶ月
|
|
|
Key secondary endpoint: Overall Response (OR) according to RECIST 1.1 determined by blinded central independent review
時間枠:up to 53 months
|
OR is defined as confirmed best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to RECIST 1.1 from date of randomization until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
up to 53 months
|
|
Key secondary endpoint: Change from baseline to Week 25 of Non-small cell lung cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score
時間枠:at baseline, at week 25
|
The NSCLC-SAQ is a 7-item patient-reported outcome measure for use in adults to assess symptoms of advanced NSCLC. It contains five domains and accompanying items that were identified as symptoms of NSCLC: cough (1 item), pain (2), dyspnea (1), fatigue (2), and appetite (1). The (total) lowest score possible is 0, and the highest (total) score possible is 20. Higher scores indicate more severe symptoms. |
at baseline, at week 25
|
|
Key secondary endpoint: Overall Survival (OS)
時間枠:up to 53 months
|
OS is defined as the time from randomization until death from any cause. |
up to 53 months
|
|
Duration of response (DoR), determined by blinded central independent review
時間枠:up to 53 months
|
DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response. |
up to 53 months
|
|
PFS determined by blinded central independent review
時間枠:up to 53 months
|
PFS is defined as the time from randomization until tumor progression or death from any cause, whichever occurs earlier. |
up to 53 months
|
|
Bi-compartmental PFS, determined by blinded central independent review
時間枠:up to 53 months
|
Bi-compartmental PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier. |
up to 53 months
|
|
OR determined by blinded central independent review
時間枠:up to 53 months
|
OR is defined as confirmed best overall response of CR or PR, from date of randomization until the earliest progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
up to 53 months
|
|
Change from baseline to Week 25 in the NSCLC-SAQ pain domain score
時間枠:at baseline, at week 25
|
The individual NSCLC-SAQ items use a five-point verbal rating scale from "No <symptom> At All" to "Very severe <symptom>" or from "Never to Always," corresponding to an (item) score of 0 to 4. A higher score indicates more severe symptoms. |
at baseline, at week 25
|
|
Change from baseline to Week 25 in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) physical functioning domain score
時間枠:at baseline, at week 25
|
The EORTC QLQ-C30 is a quality of life questionnaire. It ranges from 0 to 100, higher scores equal worse outcome. |
at baseline, at week 25
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1479-0008
- 2023-504308-27-00 (レジストリ識別子:CTIS)
- U1111-1294-1407 (その他の識別子:WHO International Clinical Trials Registry Platform (ICTRP))
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD 共有時間枠
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD 共有アクセス基準
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。